The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment

Detalhes bibliográficos
Autor(a) principal: Rodrigues, Manuel Lima
Data de Publicação: 2010
Outros Autores: Lamas, Nuno Jorge, Fernandes, Ana Valle, Cruz, Andrea, Vieira, Artur Jorge Gomes, Oliveira, Pedro, Pedrosa, Jorge, Castro, António G., Reis, R. M., Baltazar, Fátima, Almeida, Armando
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/1822/29372
Resumo: The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.
id RCAP_6d94b5f66899545d6784839ec80993f3
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/29372
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatmentNeurogenic laryngitisNasogastric intubation (NGI) modelQuantitative real-time QRT-PCRSelective COX-2 inhibitorTumor necrosis factor-a (TNF-a)Science & TechnologyThe selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.OBJECTIVE: A randomised experimental study was used to evaluate the therapeutic effect of a selective cyclooxygenase-2 (COX-2) inhibitor in neurogenic laryngitis. MATERIALS AND METHODS: Male Wistar Han rats were subjected to the nasogastric intubation model (NGI) of laryngitis for 1 and 2 weeks. The NGI animals were divided into three groups: (1) treated with COX-2 inhibitor Etoricoxib, (2) vehicle and (3) non-intubated animals. A fourth group of animals was submitted to NGI only. Laryngeal sections were immunostained for substance P (SP) and calcitonin gene-related peptide (CGRP) fibre-immunoreactivity (IR) and quantification of COX-2 positive cells through stereological analysis. The expression of COX-2, interleukins IL-1beta, IL-6, IL-10 and tumour necrosis factor-alpha (TNF-alpha) was determined by quantitative real time QRT-PCR. TREATMENT: Etoricoxib (6 mg/kg/day) was prepared in 0.9% sterile saline with 5% glucose (vehicle) and administered daily during 1 or 2 weeks. RESULTS: Treatment for 1 week with Etoricoxib attenuated the CGRP-IR fibre depletion, the COX-2-IR increased cell number and the TNF-alpha and COX-2 mRNA increased levels induced by NGI. Two weeks of treatment had no beneficial effect. CONCLUSIONS: Etoricoxib is effective in neurogenic laryngitis for limited periods of administration, indicating that selective COX-2 inhibitors should be evaluated in the future.This study was supported by Fundacao Calouste Gulbenkian Project No 74551 and Fundacao Grunenthal (Portugal).SpringerUniversidade do MinhoRodrigues, Manuel LimaLamas, Nuno JorgeFernandes, Ana ValleCruz, AndreaVieira, Artur Jorge GomesOliveira, PedroPedrosa, JorgeCastro, António G.Reis, R. M.Baltazar, FátimaAlmeida, Armando20102010-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/29372eng1023-383010.1007/s00011-010-0185-520349107http://link.springer.com/article/10.1007%2Fs00011-010-0185-5info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:51:05Zoai:repositorium.sdum.uminho.pt:1822/29372Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:49:55.343430Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
title The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
spellingShingle The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
Rodrigues, Manuel Lima
Neurogenic laryngitis
Nasogastric intubation (NGI) model
Quantitative real-time QRT-PCR
Selective COX-2 inhibitor
Tumor necrosis factor-a (TNF-a)
Science & Technology
title_short The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
title_full The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
title_fullStr The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
title_full_unstemmed The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
title_sort The selective COX-2 inhibitor etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment
author Rodrigues, Manuel Lima
author_facet Rodrigues, Manuel Lima
Lamas, Nuno Jorge
Fernandes, Ana Valle
Cruz, Andrea
Vieira, Artur Jorge Gomes
Oliveira, Pedro
Pedrosa, Jorge
Castro, António G.
Reis, R. M.
Baltazar, Fátima
Almeida, Armando
author_role author
author2 Lamas, Nuno Jorge
Fernandes, Ana Valle
Cruz, Andrea
Vieira, Artur Jorge Gomes
Oliveira, Pedro
Pedrosa, Jorge
Castro, António G.
Reis, R. M.
Baltazar, Fátima
Almeida, Armando
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Rodrigues, Manuel Lima
Lamas, Nuno Jorge
Fernandes, Ana Valle
Cruz, Andrea
Vieira, Artur Jorge Gomes
Oliveira, Pedro
Pedrosa, Jorge
Castro, António G.
Reis, R. M.
Baltazar, Fátima
Almeida, Armando
dc.subject.por.fl_str_mv Neurogenic laryngitis
Nasogastric intubation (NGI) model
Quantitative real-time QRT-PCR
Selective COX-2 inhibitor
Tumor necrosis factor-a (TNF-a)
Science & Technology
topic Neurogenic laryngitis
Nasogastric intubation (NGI) model
Quantitative real-time QRT-PCR
Selective COX-2 inhibitor
Tumor necrosis factor-a (TNF-a)
Science & Technology
description The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.
publishDate 2010
dc.date.none.fl_str_mv 2010
2010-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/29372
url http://hdl.handle.net/1822/29372
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1023-3830
10.1007/s00011-010-0185-5
20349107
http://link.springer.com/article/10.1007%2Fs00011-010-0185-5
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133081917980672

Registros relacionados